Abstract Current SARS-CoV-2 Omicron subvariants impose a heavy burden on global health
systems by evading immunity from most developed neutralizing antibodies and vaccines …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) Omicron variant sub-
lineages spread rapidly worldwide, mostly due to their immune-evasive properties. This has …

The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective
countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for …

The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with increased transmissibility and profound immune-escape capacity makes it …

Abstract As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading
worldwide, development of antibodies and vaccines to confer broad and protective activity is …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variants have risen to dominance, which contains far more mutations in the spike protein in …

SARS-CoV-2 variants with adaptive mutations have continued to emerge, causing fresh
waves of infection even amongst vaccinated population. The development of broad …

Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …

The highly mutated and transmissible Omicron (BA. 1) and its more contagious lineage BA.
2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 …

With the widespread vaccinations against coronavirus disease 2019 (COVID-19), we are
witnessing gradually waning neutralizing antibodies and increasing cases of breakthrough …